News
07-31-2013, 03:17 AM
Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.
More... (http://www.news-medical.net/news/20130731/Nektar-completes-enrollment-in-BEACON-trial-of-NKTR-102-in-patients-with-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20130731/Nektar-completes-enrollment-in-BEACON-trial-of-NKTR-102-in-patients-with-metastatic-breast-cancer.aspx)